Atlas Trials

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

Clinical trial NCT07674810 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07674810
Sponsor
M.D. Anderson Cancer Center
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2026-12-31
Primary completion
2027-04-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.